OPA1 and breast carcinoma: Finally, we tested whether N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-YL)-3-methyl-1-PH+ (MYLS22), the first in class safe and specific Opa1 inhibitor discovered in our laboratory, could recapitulate the effects of genetic OPA1 silencing on breast cancer cell phenotype.